Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/hepatitis-b-virus-vaccine-0JL0O50YG4
References (13)
-
W. Szmuness, C. Stevens, E. Zang, E. Harley, A. Kellner (1981)
A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final reportHepatology, 1
-
W. Szmuness, W. Szmuness, C. Stevens, E. Harley, Edith Zang, P. Taylor, H. Alter (1981)
The immune response of healthy adults to a reduced dose of hepatitis B vaccineJournal of Medical Virology, 8
-
S. Krugman, H. Holley, J. Davidson, M. Simberkoff, N. Matsaniotis (1981)
Immunogenic effect of inactivated hepatitis B vaccine: Comparison of 20 μg and 40 μg dosesJournal of Medical Virology, 8
-
W. Szmuness, C. Stevens, E. Harley, E. Zang, W. Oleszko, D. William, R. Sadovsky, J. Morrison, A. Kellner (1980)
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.The New England journal of medicine, 303 15
-
J. Dienstag, Diane Ryan (1982)
Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization?American journal of epidemiology, 115 1
-
E. Tabor, L. Barker, R. Gerety (1981)
Failure to detect infectious hepatitis b virus using high dose safety test for hepatitis b vaccineJournal of Medical Virology, 6
-
A. Mulley, M. Silverstein, J. Dienstag (1982)
Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.The New England journal of medicine, 307 11
-
D. Francis, S. Hadler, S. Thompson, J. Maynard, D. Ostrow, N. Altman, E. Braff, P. O'Malley, D. Hawkins, F. Judson, K. Penley, T. Nylund, G. Christie, F. Meyers, J. Moore, A. Gardner, I. Doto, J. Miller, G. Reynolds, B. Murphy, C. Schable, B. Clark, J. Curran, A. Redeker (1982)
The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.Annals of internal medicine, 97 3
-
W. Szmuness, C. Stevens, E. Harley, E. Zang, H. Alter, P. Taylor, Anita Vera, George Chen, A. Kellner (1982)
Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection.The New England journal of medicine, 307 24
-
J. Dienstag, C. Stevens, A. Bhan, W. Szmuness (1982)
Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen.Annals of internal medicine, 96 5
-
L. Seeff, E. Wright, H. Zimmerman, H. Alter, A. Dietz, B. Felsher, J. Finkelstein, P. García-Pont, Gerin Jl, H. Greenlee, J. Hamilton, P. Holland, P. Kaplan, T. Kiernan, R. Koff, C. Leevy, V. McAuliffe, N. Nath, R. Purcell, E. Schiff, C. Schwartz, C. Tamburro, Z. Vlahcevic, R. Zemel, D. Zimmon (1978)
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.Annals of internal medicine, 88 3
-
Hilleman Mr (1980)
New developments with new vaccines.Progress in Clinical and Biological Research, 47
-
W. Szmuness, W. Oleszko, C. Stevens, A. Goodman (1981)
PASSIVE.ACTIVE IMMUNISATION AGAINST HEPATITIS B: IMMUNOGENICITY STUDIES IN ADULT AMERICANSThe Lancet, 317
- Publisher
- American Medical Association
- Copyright
- Copyright © 1983 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.1983.03340160031027
- Publisher site
- See Article on Publisher Site
Abstract
At the Duke University Medical Center, Durham, NC, there are approximately ten recognized hepatitis B virus (HBV) infections per year in employees. The hospital's hepatitis control program costs $91,995 per year, including costs for workman's compensation, hyperimmune globulin, laboratory tests, lost revenue, liability, personnel, and medical treatment. A program to immunize high-risk medical center personnel and to accommodate residual HBV problems in nonimmunized employees would cost $206,304 in the first year. By seven years the cumulative costs of an immunization program would equal those without a program and at ten years would be cost saving ($746,742 with program v $919,950 without a program). Given certain assumptions, HBV vaccine is a cost-beneficial alternative for a major employee health hazard. (JAMA 1983;250:2145-2150)
Journal
JAMA – American Medical Association
Published: Oct 28, 1983